Yoon Jong Choi

Blueprint Medicines (United States)

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Blueprint Medicines (United States)

Research Subjects

Research Interests

Yoon Jong Choi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

Jian Guo
Blueprint Medicines Corporation, Cambridge, Massachusetts
56 shared publications
Kerrie L. Faia
Blueprint Medicines, Inc., Cambridge, MA, USA
56 shared publications
Lakshmi Muthuswamy
Blueprint Medicines Corporation, Cambridge, Massachusetts
56 shared publications
Liang Yuan
Blueprint Medicines Corporation, Cambridge, Massachusetts
56 shared publications
Maxine Chen
Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
56 shared publications
Nealia C. House
Blueprint Medicines Corporation, Cambridge, Massachusetts
56 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Cell cycle profiling in CCNE1-amplified and CCNE1-normal cell lines treated with BLU-222 for 24h.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Cell cycle profiling in CCNE1-amplified and CCNE1-normal cell lines treated with BLU-222 for 24h.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluation of CDK2-dependency in cell lines using CCLE/DepMap.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluation of CDK2-dependency in cell lines using CCLE/DepMap.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluating ploidy and ubiquitin-related pathways in BLU-222 responders versus non-responders.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S9 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluating ploidy and ubiquitin-related pathways in BLU-222 responders versus non-responders.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Endometrial PDX model biomarker expression, PK/PD, and body weight measurements.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S10 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Endometrial PDX model biomarker expression, PK/PD, and body weight measurements.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
BLU-222 + ribociclib PK and body weight measurements in OVK18, MFE-296, OVCAR-3 T2A xenograft studies.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S14 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
BLU-222 + ribociclib PK and body weight measurements in OVK18, MFE-296, OVCAR-3 T2A xenograft studies.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
In vitro BLU-222 + ribociclib ZIP synergy plots
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S13 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
In vitro BLU-222 + ribociclib ZIP synergy plots
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluating Rb and p16 as markers of response to BLU-222 in CCNE1-high cell lines
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Evaluating Rb and p16 as markers of response to BLU-222 in CCNE1-high cell lines
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Supplementary Tables from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Cyclin E1, Rb, and p16 protein expression measured by Western blot in ovarian and endometrial cell lines.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S7 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
Cyclin E1, Rb, and p16 protein expression measured by Western blot in ovarian and endometrial cell lines.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
CDK2-depletion induces antiproliferative effect in CCNE1-amplified cell lines.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
by Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, et al.
CDK2-depletion induces antiproliferative effect in CCNE1-amplified cell lines.

Show all